Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

CompletedOBSERVATIONAL
Enrollment

2,948

Participants

Timeline

Start Date

February 13, 2011

Primary Completion Date

October 3, 2019

Study Completion Date

October 3, 2019

Conditions
Type 2 Diabetes
Trial Locations (46)

D5550C00001

Research Site, Aichi

Research Site, Akita

Research Site, Aomori

Research Site, Chiba

Research Site, Ehime

Research Site, Fukuoka

Research Site, Fukushima

Research Site, Gifu

Research Site, Gunma

Research Site, Hiroshima

Research Site, Hokkaido

Research Site, Hyōgo

Research Site, Ibaraki

Research Site, Ishikawa

Research Site, Kagawa

Research Site, Kagoshima

Research Site, Kanagawa

Research Site, Kochi

Research Site, Kumamoto

Research Site, Kyoto

Research Site, Mie

Research Site, Miyagi

Research Site, Miyazaki

Research Site, Nagano

Research Site, Nagasaki

Research Site, Nara

Research Site, Niigata

Research Site, Numakunai

Research Site, Okayama

Research Site, Okinawa

Research Site, Osaka

Research Site, Ōita

Research Site, Saga

Research Site, Saitama

Research Site, Shiga

Research Site, Shimane

Research Site, Shizuoka

Research Site, Tochigi

Research Site, Tokushima

Research Site, Tokyo

Research Site, Tottori

Research Site, Toyama

Research Site, Wakayama

Research Site, Yamagata

Research Site, Yamaguchi

Research Site, Yamanashi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT01817569 - Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection) | Biotech Hunter | Biotech Hunter